Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250645 | PMC |
| http://dx.doi.org/10.1111/ene.14827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis.
Ir J Med Sci
December 2024
Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Background: Increasing data are available on the use and efficacy of rituximab (RTX) in patients with anti-muscle-specific tyrosine kinase (MuSK)-positive myasthenia gravis (MG), especially those steroid-dependent or unresponsive to traditional immunotherapies.
Aims: We aimed to evaluate the clinical characteristics and treatment responses of adult patients with generalized anti-MuSK-positive MG treated with RTX.
Methods: We retrospectively recruited 16 patients who were on RTX, between January 2010 and September 2023.
An unusual initiation of an ocular form of MuSK-positive myasthenia gravis after magnesium administration: a rare case report.
Ann Med Surg (Lond)
July 2024
Department of Neurology, Alwatani Hospital, Hama.
Introduction And Importance: The primary clinical symptom in people with myasthenia gravis (MG) is muscle weakness that gets worse with activity and gets better with rest; often, the first symptoms are ocular ones, such as ptosis and double vision. On the other hand, individuals with anti-muscle-specific tyrosine kinase may present with unusual symptoms. Nonetheless, it is hypothesized that muscle-specific tyrosine kinase antibodies may be present when no antibodies are present, along with bulbar and respiratory symptoms.
View Article and Find Full Text PDFImmunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Front Immunol
August 2023
Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile. On the other hand, acetylcholine receptor (AChR) MG, the most prevalent form of MG, is characterized by immunoglobulin (Ig)G1 and IgG3 antibodies to the AChR.
View Article and Find Full Text PDFHow to manage MuSK antibody-positive myasthenic crisis during pregnancy?
Ideggyogy Sz
March 2022
Kütahya Health Sciences University Faculty of Medicine, Department of Neurology, Turkey.
Myasthenia gravis (MG) is an autoimmune disease that is characterised by the formation of antibodies against acetylcholine receptors in the postsynaptic membrane of the neuromuscular junction. The course of the disease cannot be predicted during pregnancy. A subtype of MG with positive muscle-specific receptor tyrosine kinase (anti-MuSK) antibodies exhibits more localised clinical characteristics and a poor response to treatment compared with the disease subtype that involves positivity for acetylcholine receptor antibodies.
View Article and Find Full Text PDFRituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis.
Cureus
November 2021
Internal Medicine, Larkin Health System, South Miami, USA.
Myasthenia gravis affects the neuromuscular junction of the skeletal muscles. It results in muscle weakness involving skeletal muscles (diaphragm, extraocular muscles) and myasthenic crisis. Treatment options for myasthenia gravis management have expanded, including azathioprine, corticosteroids, plasma exchange, and tacrolimus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!